FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255015632> ?p ?o ?g. }

• W2255015632 endingPage "21361" @default.
• W2255015632 startingPage "21353" @default.
• W2255015632 abstract "// Marta Lionetti 1 , Marzia Barbieri 2 , Martina Manzoni 1 , Sonia Fabris 2 , Cecilia Bandini 2 , Katia Todoerti 3 , Filomena Nozza 3 , Davide Rossi 4 , Pellegrino Musto 3 , Luca Baldini 1, 2 , Antonino Neri 1, 2 1 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy 2 Hematology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy 3 Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy 4 Department of Translational Medicine, Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy Correspondence to: Antonino Neri, e-mail: antonino.neri@unimi.it Marta Lionetti, e-mail: marta.lionetti@unimi.it Keywords: multiple myeloma, plasma cell leukemia, TP53 , next-generation sequencing, mutational analysis Received: October 9, 2015     Accepted: January 19, 2016     Published: February 08, 2016 ABSTRACT The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications." @default.
• W2255015632 created "2016-06-24" @default.
• W2255015632 creator A5002654651 @default.
• W2255015632 creator A5015790909 @default.
• W2255015632 creator A5015825372 @default.
• W2255015632 creator A5022766236 @default.
• W2255015632 creator A5035934730 @default.
• W2255015632 creator A5042629318 @default.
• W2255015632 creator A5044869604 @default.
• W2255015632 creator A5046669954 @default.
• W2255015632 creator A5053958006 @default.
• W2255015632 creator A5058553911 @default.
• W2255015632 creator A5071379560 @default.
• W2255015632 date "2016-02-08" @default.
• W2255015632 modified "2023-09-27" @default.
• W2255015632 title "Molecular spectrum of <i>TP53</i> mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature" @default.
• W2255015632 cites W1549044564 @default.
• W2255015632 cites W192072239 @default.
• W2255015632 cites W1948765411 @default.
• W2255015632 cites W1957151369 @default.
• W2255015632 cites W1979457403 @default.
• W2255015632 cites W1986076152 @default.
• W2255015632 cites W1995068068 @default.
• W2255015632 cites W2002909416 @default.
• W2255015632 cites W2003426156 @default.
• W2255015632 cites W2003599195 @default.
• W2255015632 cites W2005889402 @default.
• W2255015632 cites W2006680755 @default.
• W2255015632 cites W2015880063 @default.
• W2255015632 cites W2020308683 @default.
• W2255015632 cites W2032273268 @default.
• W2255015632 cites W2047004797 @default.
• W2255015632 cites W2053445935 @default.
• W2255015632 cites W2059581635 @default.
• W2255015632 cites W2063669247 @default.
• W2255015632 cites W2065602617 @default.
• W2255015632 cites W2069827448 @default.
• W2255015632 cites W2086442724 @default.
• W2255015632 cites W2087843841 @default.
• W2255015632 cites W2092130062 @default.
• W2255015632 cites W2098592123 @default.
• W2255015632 cites W2104195581 @default.
• W2255015632 cites W2114366538 @default.
• W2255015632 cites W2123429489 @default.
• W2255015632 cites W2132838873 @default.
• W2255015632 cites W2151037269 @default.
• W2255015632 cites W2159114387 @default.
• W2255015632 cites W2163662388 @default.
• W2255015632 cites W2169846247 @default.
• W2255015632 cites W2170387305 @default.
• W2255015632 cites W2312641146 @default.
• W2255015632 cites W65850433 @default.
• W2255015632 cites W66769261 @default.
• W2255015632 cites W77810648 @default.
• W2255015632 cites W2415509704 @default.
• W2255015632 doi "https://doi.org/10.18632/oncotarget.7241" @default.
• W2255015632 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5008290" @default.
• W2255015632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26870891" @default.
• W2255015632 hasPublicationYear "2016" @default.
• W2255015632 type Work @default.
• W2255015632 sameAs 2255015632 @default.
• W2255015632 citedByCount "35" @default.
• W2255015632 countsByYear W22550156322016 @default.
• W2255015632 countsByYear W22550156322017 @default.
• W2255015632 countsByYear W22550156322018 @default.
• W2255015632 countsByYear W22550156322019 @default.
• W2255015632 countsByYear W22550156322020 @default.
• W2255015632 countsByYear W22550156322021 @default.
• W2255015632 countsByYear W22550156322022 @default.
• W2255015632 crossrefType "journal-article" @default.
• W2255015632 hasAuthorship W2255015632A5002654651 @default.
• W2255015632 hasAuthorship W2255015632A5015790909 @default.
• W2255015632 hasAuthorship W2255015632A5015825372 @default.
• W2255015632 hasAuthorship W2255015632A5022766236 @default.
• W2255015632 hasAuthorship W2255015632A5035934730 @default.
• W2255015632 hasAuthorship W2255015632A5042629318 @default.
• W2255015632 hasAuthorship W2255015632A5044869604 @default.
• W2255015632 hasAuthorship W2255015632A5046669954 @default.
• W2255015632 hasAuthorship W2255015632A5053958006 @default.
• W2255015632 hasAuthorship W2255015632A5058553911 @default.
• W2255015632 hasAuthorship W2255015632A5071379560 @default.
• W2255015632 hasBestOaLocation W22550156321 @default.
• W2255015632 hasConcept C121608353 @default.
• W2255015632 hasConcept C126322002 @default.
• W2255015632 hasConcept C143998085 @default.
• W2255015632 hasConcept C159654299 @default.
• W2255015632 hasConcept C194409129 @default.
• W2255015632 hasConcept C203014093 @default.
• W2255015632 hasConcept C2776364478 @default.
• W2255015632 hasConcept C2778461978 @default.
• W2255015632 hasConcept C2780353925 @default.
• W2255015632 hasConcept C2780411336 @default.
• W2255015632 hasConcept C36394416 @default.
• W2255015632 hasConcept C71924100 @default.
• W2255015632 hasConcept C72563966 @default.
• W2255015632 hasConceptScore W2255015632C121608353 @default.
• W2255015632 hasConceptScore W2255015632C126322002 @default.
• W2255015632 hasConceptScore W2255015632C143998085 @default.

• next